2 weeks Ago By ABMN Staff
Legal & General Group Plc trimmed its position in Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM – Free Report ) by 7.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The fund owned 51,803 shares of the company’s stock after selling 4,244 shares during the quarter. Legal & General Group Plc’s holdings in Rhythm Pharmaceuticals were worth $2,900,000 as of its most recent SEC filing. Several other institutional investors and hedge funds also recently bought and sold shares of the company.
Invesco Ltd. raised its position in shares of Rhythm Pharmaceuticals by 14.5% during the 4th quarter.
Invesco Ltd. now owns 302,846 shares of the company’s stock valued at $16,953,000 after buying an additional 38,429 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at $1,732,000.
Wells Fargo & Company MN lifted its stake in shares of Rhythm Pharmaceuticals by 26.6% in the 4th quarter. Wells Fargo & Company MN now owns 37,324 shares of the company’s stock valued at $2,089,000 after purchasing an additional 7,850 shares during the last quarter.
Cinctive Capital Management LP acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $4,633,000. Finally, Bryce Point Capital LLC acquired a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth about $1,098,000. Rhythm Pharmaceuticals Stock Up 1.
0 % Shares of NASDAQ:RYTM opened at $59.84 on Thursday. Rhythm Pharmaceuticals, Inc.
has a fifty-two week low of $35.17 and a fifty-two week high of $68.58.
The firm’s 50 day moving average price is $54.88 and its 200 day moving average price is $55.83.
The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -13.82 and a beta of 2.
32. Analyst Upgrades and Downgrades RYTM has been the subject of several research analyst reports. Canaccord Genuity Group increased their target price on shares of Rhythm Pharmaceuticals from $81.
00 to $92.00 and gave the stock a “buy” rating in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a “buy” rating and set a $80.
00 price objective (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Needham & Company LLC reissued a “buy” rating and issued a $66.
00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Wells Fargo & Company raised their price target on Rhythm Pharmaceuticals from $80.00 to $91.
00 and gave the stock an “overweight” rating in a research report on Monday, April 7th. Finally, Jefferies Financial Group initiated coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a “buy” rating and a $80.
00 price objective on the stock. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Rhythm Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $74.92.
Read Our Latest Stock Analysis on Rhythm Pharmaceuticals Insider Buying and Selling at Rhythm Pharmaceuticals In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $76,129.
83. Following the transaction, the insider now owns 2,657 shares of the company’s stock, valued at $157,905.51.
The trade was a 32.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink .
Also, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.
00. Following the sale, the executive vice president now owns 40,370 shares of the company’s stock, valued at approximately $2,078,247.60.
This represents a 65.01 % decrease in their position. The disclosure for this sale can be found here .
Insiders have sold 146,641 shares of company stock worth $8,112,177 over the last three months. Insiders own 5.60% of the company’s stock.
About Rhythm Pharmaceuticals ( Free Report ) Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. Featured Stories Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM – Free Report ). Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
